Profile
ACHL VRTX REGN SGEN ALNY ARGX
Company Name Achilles Therapeutics plc Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Alnylam Pharmaceuticals, Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $60.83M $130.72B $58.75B $43.15B $35.25B $34.28B
Employees 0.20K 6.10K 15.11K 3.26K 2.23K 1.60K
CEO Dr. Iraj Ali Ph.D. Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Dr. Yvonne L. Greenstreet M.B.A., M.D. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
ACHL VRTX REGN SGEN ALNY ARGX
Quant Rating Score 3 2 4 3 1 3
Quant Rating Neutral Sell Buy Neutral Strong Sell Neutral
Trading
ACHL VRTX REGN SGEN ALNY ARGX
Last Close $1.48 $485.89 $549.28 $228.74 $230.5 $587.59
High 52 $1.49 $516.74 $1201.76 $228.74 $296.75 $671.75
Low 52 $0.7 $392.81 $546.39 $228.74 $143.31 $356.01
Price vs. 52 Week High -0.67 % -5.97 % -54.29 % 0 % -22.33 % -12.53 %
Price vs. 52 Week Low 111.43 % 23.7 % 0.53 % 0 % 60.84 % 65.05 %
Total Return
ACHL VRTX REGN SGEN ALNY ARGX
1 Month Return 2.78 % -5.42 % -18.95 % 0 % -8.97 % -4.33 %
3 Month Return 29.82 % 15.14 % -19.41 % 0 % -6.4 % -8.26 %
6 Month Return 49.49 % -2.58 % -44.96 % 0 % -22.31 % 8.15 %
9 Month Return 72.31 % -0.51 % -49.4 % 0 % -3.97 % 26.8 %
YTD Return 29.82 % 20.66 % -22.89 % 0 % -2.04 % -4.46 %
1 Year Return 81.71 % 23.6 % -39.05 % 0 % 58.62 % 60.46 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL VRTX REGN SGEN ALNY ARGX
Dividend Yield Percentage (TTM) - - 0.16 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -42.87 % -1.65 % 5.37 % -2.27 % -0.24 % -44.32 %
Dividend Per Share (TTM) - - 0.88 % - - -
Payout Ratio (TTM) - - - - - -
Profitability
ACHL VRTX REGN SGEN ALNY ARGX
Gross Profit Margin TTM - 86.09 % 84.47 % 72.37 % 85.62 % 46.33 %
Return on Assets TTM -54.64 % -2.38 % 11.69 % -11.76 % -6.56 % 13.45 %
Return on Equity TTM -54.57 % -3.28 % 14.77 % -16.53 % 905.33 % 16.83 %
Return on Capital Employed TTM -69.28 % -1.3 % 10.89 % -16.87 % -5.79 % -0.31 %
Net Income Per EBT TTM 100.74 % -215.53 % 92.32 % 100.55 % 73.71 % 25990.14 %
EBT Per Ebit TTM 92.18 % -100.69 % 118.85 % 94.01 % 213.34 % -18.79 %
EBIT Per Revenue TTM - -2.24 % 28.32 % -36.09 % -7.87 % -0.77 %
Cash Flow To Debt Ratio TTM -876.73 % -28.16 % 222.76 % -185.98 % -0.64 % -201.37 %
Receivables Turnover TTM - 6.84 2.29 1.98 5.55 2.46
Payables Turnover TTM 0.83 3.71 2.79 1.54 3.66 1.83
Inventory Turnover TTM - 1.27 0.71 0.65 4.12 2.93
Fixed Asset Turnover TTM - 425.82 % 308.76 % 256.83 % 323.99 % 5106.8 %
Asset Turnover TTM - 48.84 % 37.61 % 34.46 % 53.02 % 35.83 %
Operating Cash Flow Per Share TTM -0.79 -1.91 41.08 -1.12 -0.06 -1.07
Free Cash Flow Per Share TTM -0.8 -3.07 33.43 -1.62 -0.33 -1.09
Cash Per Share TTM 212.86 % 2375.11 % 16647.4 % 657.5 % 2095.42 % 4597.04 %
Operating Cash Flow Sales Ratio TTM - -4.48 % 31.13 % -16.85 % -0.37 % -3.54 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.33 % 160.43 % 81.38 % 144.14 % 512.38 % 102.26 %
Cash Flow Coverage Ratios TTM -876.73 % -28.16 % 222.76 % -185.98 % -0.64 % -201.37 %
Price To Free Cash Flows Ratio TTM -1.87 -165.4 16.33 -141.85 -827.74 -444.85
Price To Operating Cash Flows Ratio TTM -1.89 -266.09 13.37 -203.89 -4192.79 -531.16
Price Cash Flow Ratio TTM -1.89 -266.09 13.37 -203.89 -4192.79 -531.16
Income Statement (TTM)
ACHL VRTX REGN SGEN ALNY ARGX
Revenue $0B $11.02B $14.2B $1.96B $2.25B $2.19B
Gross Profit $-0B $9.49B $12.23B $1.55B $1.92B $1.96B
Gross Profit Ratio 0% 86.11% 86.13% 79.1% 85.62% 89.62%
EBITDA $-0.07B $0.49B $5.32B $-0.62B $-0.18B $0B
Net Income $-0.07B $-0.54B $4.41B $-0.61B $-0.28B $0.83B
EPS Diluted -1.74 -2.08 38.34 -3.3 -2.16 12.78
Balance Sheet (MRQ)
ACHL VRTX REGN SGEN ALNY ARGX
Long Term Debt $0B $1.66B $2.7B $0.04B $0B $0.03B
Total Liabilities $0.02B $6.12B $8.41B $0.87B $4.17B $0.68B
Total Equity $0.14B $16.41B $29.35B $2.8B $0.07B $5.31B
Total Investments $0B $6.65B $6.52B $1.42B $1.73B $1.82B
Total Debt $0B $1.75B $2.7B $0.04B $1.3B $0.04B
Total Assets $0.16B $22.53B $37.76B $3.67B $4.24B $5.99B
Cash Flow Statement (TTM)
ACHL VRTX REGN SGEN ALNY ARGX
Net Income $-0.07B $-0.54B $4.41B $-0.61B $-0.28B $0.8B
Inventory $0B $-0.52B $-0.62B $-0.23B $0.01B $-0.09B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $-0.49B $4.42B $-0.45B $-0.01B $-0.08B
Capital Expenditure $-0B $-0.3B $-0.76B $-0.08B $-0.03B $-0B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 19.005
ABCL AbCellera Biologics Inc. 2.425
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.83
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 0.9009
ABPWW 0.0465
ABSI Absci Corporation 3.095
ABUS Arbutus Biopharma Corporation 3.16
ABVC ABVC BioPharma, Inc. 0.8525
ABVX Abivax SA American Depositary Shares 6.44
ACAD ACADIA Pharmaceuticals Inc. 14.72
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.5229
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 1.99
ACIU AC Immune SA 1.48
ACLX Arcellx, Inc. 62.06
ACRV Acrivon Therapeutics, Inc. Common Stock 1.82
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 118.32
BIB ProShares Ultra Nasdaq Biotechnology 0 41.32
IBBQ Invesco Nasdaq Biotechnology ETF 0 19.8
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 5.7275
Unlock